您当前位置: 首页  >  学术讲座

讲准字195号:硫化氢:肿瘤治疗的新策略?(Is hydrogen sulfide a new strategy for cancer therapy?)

发布时间:2018-06-12|浏览次数:

题目:硫化氢:肿瘤治疗的新策略?(Is hydrogen sulfide a new strategy for cancer therapy?)

主讲:Jinsong Bian(卞劲松)

时间:2018年6月13日 14:30

地点:医学院3号楼2107

主办:医学院

 

主讲简介:Jinsong Bian(卞劲松),National University of Singapore School of Medicine终身教授,研究主任。研究专长:药理学。卞劲松,新加坡国立大学医学院药理学系终身教授、博士生导师,新加坡国立大学药物研发中心(NUSDrug Development Unit)常务副主任(Deputy director);医学院药理学系科研主任(Research Director);药理学气体分子实验室负责人;新加坡国家医学研究基金(National Medical Research Council)评审终审委员会委员、新加坡国家新药管理与评审中心评审专家;美国《Journal of Alzhemier’s Disease》《Frontiers in Pharmacology》等13本国际杂志特辑主编,杂志副主编、编委,亚洲血管生物学会专家委员会顾问及科学委员会委员;历届国际及欧洲硫化氢生物学学会科学顾问委员。多国国际课题申报评审专家;JCI, Circulation 及Circulation Research等60余本国际权威杂志审稿人及特邀编辑。近年来主持国家级课题15项,资助总金额约$800万,合作类课题$400万。组建气体分子药理学实验室。已发表SCI收录英文全文一百余篇,H-指数40,累积影响因子500多分。多篇代表论著发表在Circ Res(影响因子13.965)、JASN(影响因子9.665)、PNAS(影响因子9.661)、ARS(影响因子7.407)等国际著名期刊上。被同行公认为硫化氢研究领域前沿实验室之一,受美国生理学会、国际气体分子学会等国际重要学术团体特邀,在重要国际会议及学术机构作专题学术报告七十余场,并多次应国际权威杂志如 Antioxidant & Redox Signaling的邀请撰写大型专家综述。因科研成果突而或2015/2016年度新加坡国立大学医学院优秀科研成就奖。主要研究成果有:1.率先发现PIP2可以作为一个新的第二信使调控HERG电压依赖性钾通道,此重要发现发表在心血管领域顶级杂志-Circulation Research(影响因子11.861)。2.首先发现和报道H2S对缺血心肌具有保护作用,特别是内源性H2S参与了缺血预处理的保护机制,此重要发现发表在ARS(影响因子8.456)Cardiovasc Research等杂志上。3.首先发现H2S可以治疗神经退行性变,此重要发现发表在Aging Cell(影响因子7.79)Antioxidant Redox Signal(影响因子7.407)等杂志上。4.首先发现H2S可以治疗肾性高血压,此重要发现发表在JASN(影响因子9.665)Antioxidant Redox Signal (影响因子7.407)等杂志上。5.首先发现阿片肽受体激活可以激活PLC/PKC/NHE通路以及改变细胞内Ca2+和pH水平,从而调控心肌细胞功能(JPET, JMCC)。6. 首先发现性激素对心脏保护作用的部分机制(Endocrinology)。

 

主讲内容:Hydrogen sulfide (H2S) has been recognized as the third gaseous transmitter alongside nitric oxide (NO) and carbon monoxide (CO). In the past decade, numerous studies have demonstrated an active role of H2S in the context of cancer biology. The three H2S producing enzymes namely cystathionine γ-lyase (CSE), cystathionine β-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (3MST) have been found highly expressed in numerous types of cancer. Moreover, inhibition of CBS has shown anti-tumor activity particularly in colon cancer, ovarian cancer and breast cancer, whereas the consequence of CSE or 3MST inhibition remains largely unexplored in cancer cells. Intriguingly, H2S donation at high amounts or long time duration has also been observed to induce cancer cell apoptosis in vitro and in vivo while sparing noncancerous fibroblast cells. Therefore, a bell-shaped model has been proposed to explain the role of H2S in cancer development. Specifically, endogenous H2S or relatively low level of exogenous H2S may exhibit pro-cancer effect, while exposure to H2S at higher amount or for a long period may lead to cancer cell death. This indicates that inhibition of H2S biosynthesis and H2S supplementation serve as two distinct ways for cancer treatment. This paradoxical role of H2S has stimulated the enthusiasm for the development of novel CBS inhibitors, H2S donors and H2S releasing hybrids.

 

 

欢迎广大师生参加!